✨ Medicine Distribution Notices




20 JULY 2006

NEW ZEALAND GAZETTE, No. 82

2587

Product:
Octaplas (Blood Group O)
Active Ingredient:
Plasma protein fraction 9-14g
Dosage Form:
Solution for injection
New Zealand Sponsor:
Octapharma New Zealand Limited
Manufacturer:
Octapharma Pharmazeutika Produktionsges, Vienna, Austria

Product:
Prexige
Active Ingredient:
Lumiracoxib 100mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland

Product:
Redoxon Double Action
Active Ingredients:
Ascorbic acid 1,000mg
Zinc citrate 32mg equivalent to zinc 10mg
Dosage Form:
Effervescent tablet
New Zealand Sponsor:
Bayer (NZ) Limited
Manufacturer:
Roche Products Pty Limited, Dee Why, New South Wales, Australia

Product:
Riamet
Active Ingredients:
Artemether 20mg
Lumefantrine 120mg
Dosage Form:
Tablet
New Zealand Sponsor:
Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer:
Novartis Pharma Beijing, Nanguan, Chengguan Township, Changping County, Beijing, China

Dated this 13th day of July 2006.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go4894

Consent to the Distribution of a Changed Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set out in the Schedule hereto:

Schedule

Product:
Glivec
Active Ingredient:
Imatinib mesilate 119.5mg equivalent to 100mg imatinib base
Dosage Form:
Capsule
New Zealand Sponsor:
Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland

Product:
Glivec
Active Ingredient:
Imatinib mesilate 59.75mg equivalent to 50mg imatinib base
Dosage Form:
Capsule
New Zealand Sponsor:
Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland

Product:
Glivec
Active Ingredient:
Imatinib mesilate 119.5mg equivalent to 100mg imatinib base
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland

Product:
Glivec
Active Ingredient:
Imatinib mesilate 478mg equivalent to 400mg imatinib base
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer:
Novartis Pharma Stein AG, Stein, Switzerland

Dated this 13th day of July 2006.

DON MATHESON, Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go4893

Renewal of Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2006, No 82


Gazette.govt.nz PDF NZ Gazette 2006, No 82





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of New Medicines (continued from previous page)

πŸ₯ Health & Social Welfare
13 July 2006
Medicines, Distribution, Octaplas, Prexige, Redoxon Double Action, Riamet
  • DON MATHESON, Deputy Director-General, Public Health

πŸ₯ Consent to the Distribution of a Changed Medicine

πŸ₯ Health & Social Welfare
13 July 2006
Medicines, Distribution, Glivec
  • DON MATHESON, Deputy Director-General, Public Health

πŸ₯ Renewal of Provisional Consent to the Distribution of a New Medicine

πŸ₯ Health & Social Welfare
Medicines, Provisional Consent, Renewal